Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01056835

Enrollment

Registered

2010-01-26

Start date

2009-06-30

Completion date

2014-06-30

Last updated

2015-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Allograft Nephropathy

Brief summary

The purpose of this study is to evaluate the effect of Prostaglandin I2 analogue use on the development of chronic allograft nephropathy and changes in allograft function in prevalent renal transplant recipients

Interventions

DRUGprostaglandin I2 analogue

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Inclusion criteria

* prevalent renal transplant recipients 2 years after transplantation * no history of acute rejection * stable renal function

Exclusion criteria

* history of biopsy-proven chronic allograft nephropathy * history of biopsy-proven CNI nephrotoxicity * history of biopsy-proven or clinical acute rejection * unstable trough level of CNI or extremely low level of CNI * bleeding tendency(+) * pregnancy or pregnant-willing * anticoagulation(+) * antiplatelet agent (+) * significant comorbidity(+): Acute coronary syndrome, pneumonia

Design outcomes

Primary

Measure	Time frame
graft pathology, serum creatinine, creatinine clearance, eGFR	1 year after drug administration

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026